Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

GSK Fires China R&D Chief for Misrepresenting Data

publication date: Jun 12, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
According to GlaxoSmithKline, a scientific paper published by members of its China R&D staff contained “misrepresentations.”  The British biopharma has fired Jiangwu Zhang, the head of its China R&D operation, who was listed as one of the authors. The 2010 Nature Medicine article investigated the role of interleukin-7 in autoimmune diseases. As a result of the scandal, GSK has suspended Phase I tests of GSK2618960, an experimental medicine for multiple sclerosis that was based in part on the article’s early-stage research. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...